po tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says FDA approves tirzepatide, Eli Lilly's

Mounjaro is the newest advancement in GLP-1 therapies, combining GLP-1 and GIP receptor agonists for increased weight loss effects all while minimizing side effects

They're actually strong enough to grow out now

By activating both GLP-1 and GIP receptors, tirzepatide reduces appetite and slows digestion, helping you feel full longer and improving insulin sensitivity

This happens when the GLP-1 drugs cause nerve and muscle damage to the stomach muscles, which stops food from moving through the gastrointestinal system

Understanding the potential side effects and how they might impact your daily life is crucial to making a more informed decision

This reduces the risk of hypoglycaemia compared to some other diabetes medications, though this risk increases when used alongside insulin or sulfonylureas